Plasma levels of insulin-like growth factor-1 and insulin-like growth factor binding protein-3 in women with cervical neoplasia

Journal of Gynecologic Oncology

Volumn 21, Issue 3, 2010, Pages 174-180

  Lee, Si Won ^a   Lee, Soo Yoon ^b   Lee, Sa Ra ^b   Ju, Woong ^b   Kim, Seung Cheol ^b  

^a Kwandong University College of Medicine   (South Korea)

^b Ewha Womans University School of Medicine   (South Korea)

Author keywords

Cervical neoplasia; IGF 1; IGF 1 IGFBP 3 molar ratio; IGFBP 3

Indexed keywords

SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ADULT; ARTICLE; BLOOD SAMPLING; CANCER RISK; CANCER STAGING; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; PAPILLOMAVIRUS INFECTION; PATHOLOGY; PROTEIN BLOOD LEVEL; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU;

EID: 78049452917     PISSN: 20050380     EISSN: 20050399     Source Type: Journal    
DOI: 10.3802/jgo.2010.21.3.174     Document Type: Article

References (39)

1. Preston-Martin S, Pike MC, Ross RK, Jones PA, Henderson BE. Increased cell division as a cause of human cancer. Cancer Res 1990; 50: 7415-21.
2. Kim K, Ryu SY. Major clinical research advances in gynecologic cancer 2009. J Gynecol Oncol 2009; 20: 203-9.
3. Sara VR, Hall K. Insulinlike growth factors and their binding proteins. Physiol Rev 1990; 70: 591-614.
4. Rosenfeld RG, Lamson G, Pham H, Oh Y, Conover C, De Leon DD, et al. Insulinlike growth factor-binding proteins. Recent Prog Horm Res 1990; 46: 99-159.
5. Baxter RC, Saunders H. Radioimmunoassay of Insulinlike growth factor-binding protein-6 in human serum and other body fluids. J Endocrinol 1992; 134: 133-9.
6. Furlanetto RW, Harwell SE, Frick KK. Insulinlike growth factor-I induces cyclin-D1 expression in MG63 human osteosarcoma cells in vitro. Mol Endocrinol 1994; 8: 510-7.
7. Minshall C, Arkins S, Straza J, Conners J, Dantzer R, Freund GG, et al. IL-4 and Insulinlike growth factor-I inhibit the de-cline in Bcl-2 and promote the survival of IL-3-deprived mye-loid progenitors. J Immunol 1997; 159: 1225-32.
8. LeRoith D, Werner H, Beitner-Johnson D, Roberts CT Jr. Molecular and cellular aspects of the Insulinlike growth factor I receptor Endocr Rev 1995; 16: 143-63.
9. Stewart CE, Rotwein P. Growth, differentiation, and survival: multiple physiological functions for Insulinlike growth factors. Physiol Rev 1996; 76: 1005-26.
10. Esposito DL, Blakesley VA, Koval AP, Scrimgeour AG, LeRoith D. Tyrosine residues in the C-terminal domain of the in-sulin-like growth factor-I receptor mediate mitogenic and tu-morigenic signals. Endocrinology 1997; 138: 2979-88.
11. Hongo A, D'Ambrosio C, Miura M, Morrione A, Baserga R. Mutational analysis of the mitogenic and transforming activ-ities of the Insulinlike growth factor I receptor Oncogene 1996; 12: 1231-8.
12. LeRoith D, Baserga R, Helman L, Roberts CT Jr. Insulinlike growth factors and cancer. Ann Intern Med 1995; 122: 54-9.
13. Hakam A, Yeatman TJ, Lu L, Mora L, Marcet G, Nicosia SV, et al. Expression of Insulinlike growth factor-1 receptor in hu-man colorectal cancer. Hum Pathol 1999; 30: 1128-33.
14. Xie Y, Skytting B, Nilsson G, Brodin B, Larsson O. Expression of Insulinlike growth factor-1 receptor in synovial sarcoma: as-sociation with an aggressive phenotype. Cancer Res 1999; 59: 3588-91.
15. Ferry RJ Jr, Katz LE, Grimberg A, Cohen P, Weinzimer SA. Cellular actions of Insulinlike growth factor binding proteins. Horm Metab Res 1999; 31: 192-202. (Pubitemid 29169496)
16. Arany E, Afford S, Strain AJ, Winwood PJ, Arthur MJ, Hill DJ. Differential cellular synthesis of Insulinlike growth factor binding protein-1 (IGFBP-1) and IGFBP-3 within human liver. J Clin Endocrinol Metab 1994; 79: 1871-6.
17. Ballard FJ, Knowles SE, Walton PE, Edson K, Owens PC, Mohler MA, et al. Plasma clearance and tissue distribution of labelled Insulinlike growth factor-I (IGF-I), IGF-II and des (1-3) IGF-I in rats. J Endocrinol 1991; 128: 197-204.
18. Pollak M. Insulinlike growth factor physiology and cancer risk. Eur J Cancer 2000; 36: 1224-8.
19. Giovannucci E. Insulin, Insulinlike growth factors and colon cancer: a review of the evidence. J Nutr 2001; 131(Suppl 11): 3109S-20S.
20. Yu H, Rohan T. Role of the Insulinlike growth factor family in cancer development and progression. J Natl Cancer Inst 2000; 92: 1472-89.
21. Sandhu MS, Dunger DB, Giovannucci EL. Insulin, Insulinlike growth factor-I (IGF-I), IGF binding proteins, their biologic in-teractions, and colorectal cancer. J Natl Cancer Inst 2002; 94: 972-80.
22. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, et al. Plasma Insulinlike growth factor-I and pros-tate cancer risk: a prospective study. Science 1998; 279: 563-6.
23. Wolk A, Mantzoros CS, Andersson SO, Bergstrom R, Signorello LB, Lagiou P, et al. Insulinlike growth factor 1 and prostate cancer risk: a population-based, case-control study. J Natl Cancer Inst 1998; 90: 911-5.
24. Yu H, Spitz MR, Mistry J, Gu J, Hong WK, Wu X. Plasma levels of Insulinlike growth factor-I and lung cancer risk: a case-con-trol analysis. J Natl Cancer Inst 1999; 91: 151-6.
25. Steller MA, Delgado CH, Zou Z. Insulinlike growth factor II mediates epidermal growth factor-induced mitogenesis in cer-vical cancer cells. Proc Natl Acad Sci USA 1995; 92: 11970-4.
26. Wu X, Tortolero-Luna G, Zhao H, Phatak D, Spitz MR, Follen M. Serum levels of Insulinlike growth factor I and risk of squ-amous intraepithelial lesions of the cervix. Clin Cancer Res 2003; 9: 3356-61.
27. Rinderknecht E, Humbel RE. The amino acid sequence of hu-man Insulinlike growth factor I and its structural homology with proinsulin. J Biol Chem 1978; 253: 2769-76.
28. Macaulay VM. Insulinlike growth factors and cancer. Br J Cancer 1992; 65: 311-20.
29. Rogler CE, Yang D, Rossetti L, Donohoe J, Alt E, Chang CJ, et al. Altered body composition and increased frequency of di-verse malignancies in Insulinlike growth factor-II transgenic mice. J Biol Chem 1994; 269: 13779-84.
30. Steller MA, Delgado CH, Bartels CJ, Woodworth CD, Zou Z. Overexpression of the Insulinlike growth factor-1 receptor and autocrine stimulation in human cervical cancer cells. Cancer Res 1996; 56: 1761-5.
31. Serrano ML, Romero A, Cendales R, Sanchez-Gomez M, Bravo MM. Serum levels of Insulinlike growth factor-I and-II and in-sulin-like growth factor binding protein 3 in women with squ-amous intraepithelial lesions and cervical cancer. Biomedica 2006; 26: 258-68.
32. Bustin SA, Jenkins PJ. The growth hormone-Insulinlike growth factor-I axis and colorectal cancer. Trends Mol Med 2001; 7: 447-54.
33. Gomez JM, Mourot B, Fostier A, Le Gac F. Growth hormone re-ceptors in ovary and liver during gametogenesis in female rain-bow trout (Oncorhynchus mykiss). J Reprod Fertil 1999; 115: 275-85.
34. Mathur RS, Mathur SP. In vitro downregulation of growth fac-tors by Insulinlike growth factor binding protein-3 in cervical cancer. Gynecol Oncol 2003; 91: 410-5.
35. Conover CA, Powell DR. Insulinlike growth factor (IGF)-binding protein-3 blocks IGF-I-induced receptor down-regu-lation and cell desensitization in cultured bovine fibroblasts. Endocrinology 1991; 129: 710-6.
36. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 12-9.
37. Dassonville O, Formento JL, Francoual M, Ramaioli A, Santini J, Schneider M, et al. Expression of epidermal growth factor re-ceptor and survival in upper aerodigestive tract cancer. J Clin Oncol 1993; 11: 1873-8.
38. Nakamura K, Hongo A, Kodama J, Miyagi Y, Yoshinouchi M, Kudo T Down-regulation of the Insulinlike growth factor I re-ceptor by antisense RNA can reverse the transformed pheno-type of human cervical cancer cell lines. Cancer Res 2000; 60: 760-5.
39. Berger AJ, Baege A, Guillemette T, Deeds J, Meyer R, Disbrow G, et al. Insulinlike growth factor-binding protein 3 expression increases during immortalization of cervical keratinocytes by human papillomavirus type 16 E6 and E7 proteins. Am J Pathol 2002; 161: 603-10.